Pathologic response prediction to neoadjuvant chemotherapy utilizing pretreatment near-infrared imaging parameters and tumor pathologic criteria

Table 4 Training data set results ^a

Tumor pathologic variables	Receptors (core biopsy)	Pretreatment hemoglobin parameters	Sensitivity (%)/specificity (%)	PPV (%)/NPV (%)	AUC (%) (95% CI)
IDC/ILC, NS, MC			76.2/74.3	65.7/83.1	76.9 (59.60; 95.46)
IDC/ILC, NS, MC	TN, HER2, ER		71.1/80.7	70.5/81.6	87.1 (71.54; 98.63)
		tHb	58.1/84.5	69.9 /75.9	76.7 (53.01; 96.64)
		oxyHb	52.9/86.1	71.5/73.8	76.8 (54.60; 94.34)
		deoxyHb	59.3/81.8	68.1/75.9	67.4 (40.97; 90.09)
		tHb, oxyHb	60.3/87.9	77.1/77.5	78.6 (55.46; 97.08)
		tHb, deoxyHb	64.1/85.2	74.3/78.5	74.6 (55.58; 97.31)
IDC/ILC, NS, MC	TN, HER2, ER	tHb	80.5/87.6	80.8/87.5	92.9 (82.76; 99.70)
IDC/ILC, NS, MC	TN, HER2, ER	oxyHb	79.9 /91.4	85.2/87.9	96.1 (88.91; 100.0)
IDC/ILC, NS, MC	TN, HER2, ER	deoxyHb	73.0/82.0	72.9/82.9	88.9 (74.94; 98.94)
IDC/ILC, NS, MC	TN, HER2, ER	tHb, oxyHb	92.5/95.2	92.5/95.2	98.2 (93.68; 100.0)
IDC/ILC, NS, MC	TN, HER2, ER	tHb, deoxyHb	83.9/87.2	80.7/89.7	95.1 (86.94; 99.75)

^aCI, confidence interval; deoxyHb, Deoxygenated hemoglobin; ER, Estrogen receptor; HER2, Human epidermal growth factor receptor 2; IDC, Invasive ductal carcinoma; IDC/ILC, Invasive mammary carcinoma with mixed ductal and lobular features; ILC, Invasive lobular carcinoma; MC, Mitotic count; NS, Nottingham score; oxyHb, Oxygenated hemoglobin; NPV, Negative predictive value; PPV, Positive predictive value; tHb, Total hemoglobin; TN, Triple-negative.

ISSN: 1465-542X